Management of systemic mastocytosis is an emerging challenge which requires a multidisciplinary diagnostic approach and personalized treatment strategy. Midostaurin can rapidly reduce the disease burden, also in cladribine refractory cases.
Keywords: bulky lymphadenopathy; midostaurin; purine analogue; systemic mastocytosis.
© 2020 The Authors. Clinical Case Reports published by John Wiley & Sons Ltd.